| Methods |
One site in India.
12 treatment cycles. |
| Participants |
Healthy women with proven fertility.
Excluded recent hormone use. |
| Interventions |
Lynestrenol 2 mg and EE 40 µg (N=150) versus lynestrenol 1 mg and EE 40 µg (N=150). |
| Outcomes |
Contraceptive efficacy, cycle control, nausea, weight, headache, dysmenorrhea. |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Unclear risk |
No information |
| Allocation concealment (selection bias) |
Unclear risk |
No information |
| Blinding (performance bias and detection bias)
All outcomes |
High risk |
Unblinded |
| Incomplete outcome data (attrition bias)
All outcomes |
High risk |
30 women in the lynestrenol 2 mg and 33 women in the lynestrenol 1 mg group discontinued early. Discontinuations due to side effects not described.
4 women in the lynestrenol 2 mg and 5 women in the lynestrenol 1 mg group were lost to follow up. |
